| Drug Name: | Azathioprine (446-86-6) |
|---|---|
| PubChem ID: | 2265 |
| SMILES: | CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-] |
| InchiKey: | LMEKQMALGUDUQG-UHFFFAOYSA-N |
| Therapeutic Category: | Antimetabolites, Antineoplastic Agents, Antirheumatic Agents, Immunologic Factors, Immunosuppressive Agents, Noxae |
| Molecular Weight (dalton) | : | 277.269 |
| LogP | : | 1.1458 |
| Ring Count | : | 3 |
| Hydrogen Bond Acceptor Count | : | 8 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 115.42 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|---|---|---|---|
| Allopurinol (315-30-0) | Anaemia | Synergistic | Azathioprine is firstly metabolised in the liver to mercaptopurine and then enzymatically oxidised in the liver and intestinal wall by xanthine oxidase to an inactive compound (6-thiouric acid), which is excreted. Allopurinol inhibits first-pass metabolism by xanthine oxidase | Allopurinol-azathioprine interaction |
| Allopurinol (315-30-0) | Leucocytopenia | Synergistic | Azathioprine is firstly metabolised in the liver to mercaptopurine and then enzymatically oxidised in the liver and intestinal wall by xanthine oxidase to an inactive compound (6-thiouric acid), which is excreted. Allopurinol inhibits first-pass metabolism by xanthine oxidase | Allopurinol-azathioprine interaction |
| Allopurinol (315-30-0) | Pancytopenia | Synergistic | Azathioprine is firstly metabolised in the liver to mercaptopurine and then enzymatically oxidised in the liver and intestinal wall by xanthine oxidase to an inactive compound (6-thiouric acid), which is excreted. Allopurinol inhibits first-pass metabolism by xanthine oxidase | Allopurinol-azathioprine interaction |
| Allopurinol (315-30-0) | Thrombocytopenia | Synergistic | Azathioprine is firstly metabolised in the liver to mercaptopurine and then enzymatically oxidised in the liver and intestinal wall by xanthine oxidase to an inactive compound (6-thiouric acid), which is excreted. Allopurinol inhibits first-pass metabolism by xanthine oxidase | Allopurinol-azathioprine interaction |
| Mesalazine (89-57-6) | Pancytopenia | Synergistic | The metabolism of azathioprine and mercaptopurine depends on S-methylation by thiopurine methyltransferase (TPMT) and oxidation by xanthine oxidase. An in vitro study using recombinant TPMT found that both sulfasalazine and its metabolites inhibit the activity of TPMT. | Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide |
| Trimethoprim (738-70-5) | Haematotoxicity | Additive | Not understood | Neutropenia and thrombocytopenia in renal allograft recipients treated with trimethoprim-sulfamethoxazole |
| Captopril (62571-86-2) | Anaemia | Antagonistic | Due to suppression of erythropoietin by the Captopril | Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients |
This panel provides drug-protein interaction and their ADRs along with references
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category